Reducing cholesterol could enhance T-cell cancer immunotherapy

Cleveland Clinic researchers have demonstrated for the first time that lowering blood cholesterol levels could enhance the success of a specific type of T-cell immunotherapy in fighting cancer.

The team, led by Qing Yi, MD, Ph.D., of Cleveland Clinic Lerner Research Institute studied T-cell transfer, which has shown great success in recent years. Dr. Yi previously showed that a specific subset of T-cells, called Tc9 cells, have stronger anti-tumor effects than other types of T-cells. In the newly published study, they determined the mechanisms that give Tc9 cells their anti-cancer properties and how those mechanisms might be tweaked to enhance .

Using gene profiling, the researchers discovered that Tc9 cells had much lower levels of intracellular cholesterol than other T-cells. They hypothesized that the reduced cholesterol levels might contribute to the cells' anti-tumor effects. Indeed, when cholesterol-lowering drugs were administered to the cells, anti-cancer pathways were turned on (IL-9 expression and NF-KB signaling). Furthermore, they showed in a tumor-bearing preclinical model that reducing prior to immunotherapy led to greater concentrations of IL-9 and better cancer-killing success.

Immunotherapy is a type of cancer treatment that harnesses the power of the human immune system to attack and kill cancer cells. Adoptive T-cell transfer involves transplanting T-cells engineered to recognize a certain type of cancer. Researchers have focused on many different methods to manipulate and enhance the T-cells' anti-cancer activity, such as transferring at different stages of differentiation or using certain drugs in tandem with immunotherapy.

"Our studies suggest a relatively simple, cost effective way to enhance T-cell transfer therapy," Dr. Yi said. "We hope to test our findings in clinical trials soon."


Explore further

Researchers discover new approach to stimulate an immune response against tumor cells

More information: Xingzhe Ma et al, Cholesterol negatively regulates IL-9–producing CD8+T cell differentiation and antitumor activity, The Journal of Experimental Medicine (2018). DOI: 10.1084/jem.20171576
Journal information: Journal of Experimental Medicine

Provided by Cleveland Clinic
Citation: Reducing cholesterol could enhance T-cell cancer immunotherapy (2018, May 16) retrieved 5 December 2019 from https://medicalxpress.com/news/2018-05-cholesterol-t-cell-cancer-immunotherapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments